Vitamin D is best known for its influence on skeletal health. There is growing recognition, however, that vitamin D has nonskeletal actions, which could have important implications for understanding the consequences of vitamin D deficiency. In epidemiologic studies, vitamin D deficiency has been consistently associated with an increased risk for cardiovascular disease and hypertension. Disruption of vitamin D signaling in animal models promotes hypertension, cardiac hypertrophy, and atherosclerosis. This evidence has led to the initiation of prospective randomized trials of vitamin D supplementation in individuals at risk for cardiovascular disease. The results of these trials should help to guide strategies for screening and management of vitamin D deficiency in the clinic and at the population level.


Article metrics loading...

Loading full text...

Full text loading...


Literature Cited

  1. Deluca HF. 1.  2014. History of the discovery of vitamin D and its active metabolites. BoneKEy Rep. 3:479 [Google Scholar]
  2. Ginde AA, Liu MC, Camargo CA Jr. 2.  2009. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch. Intern. Med. 169:626–32 [Google Scholar]
  3. Looker AC, Dawson-Hughes B, Calvo MS. 3.  et al. 2002. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30:771–77 [Google Scholar]
  4. Lips P, Duong T, Oleksik A. 4.  et al. 2001. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J. Clin. Endocrinol. Metab. 86:1212–21 [Google Scholar]
  5. Bouillon R, Carmeliet G, Verlinden L. 5.  et al. 2008. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29:726–76 [Google Scholar]
  6. Cheng JB, Levine MA, Bell NH. 6.  et al. 2004. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. PNAS 101:7711–15 [Google Scholar]
  7. Wang TJ, Zhang F, Richards JB. 7.  et al. 2010. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376:180–88 [Google Scholar]
  8. Rosen CJ, Abrams SA, Aloia JF. 8.  et al. 2012. IOM committee members respond to endocrine society vitamin D guideline. J. Clin. Endocrinol. Metab. 97:1146–52 [Google Scholar]
  9. Holick MF, Binkley NC, Bischoff-Ferrari HA. 9.  et al. 2011. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96:1911–30 [Google Scholar]
  10. Powe CE, Evans MK, Wenger J. 10.  et al. 2013. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N. Engl. J. Med. 369:1991–2000 [Google Scholar]
  11. Li YC, Kong J, Wei M. 11.  et al. 2002. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Investig. 110:229–38 [Google Scholar]
  12. Li YC, Qiao G, Uskokovic M. 12.  et al. 2004. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J. Steroid Biochem. Mol. Biol. 89–90:387–92 [Google Scholar]
  13. Tishkoff DX, Nibbelink KA, Holmberg KH. 13.  et al. 2008. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149:558–64 [Google Scholar]
  14. Simpson RU, Hershey SH, Nibbelink KA. 14.  2007. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J. Steroid Biochem. Mol. Biol. 103:521–24 [Google Scholar]
  15. Zhou C, Lu F, Cao K. 15.  et al. 2008. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 74:170–79 [Google Scholar]
  16. Weishaar RE, Simpson RU. 16.  1987. Vitamin D3 and cardiovascular function in rats. J. Clin. Investig. 79:1706–12 [Google Scholar]
  17. Weishaar RE, Kim SN, Saunders DE, Simpson RU. 17.  1990. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am. J. Physiol. 258:E134–E42 [Google Scholar]
  18. Nibbelink KA, Tishkoff DX, Hershey SD. 18.  et al. 2007. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J. Steroid Biochem. Mol. Biol. 103:533–37 [Google Scholar]
  19. Simpson RU, Thomas GA, Arnold AJ. 19.  1985. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J. Biol. Chem. 260:8882–91 [Google Scholar]
  20. Walters MR, Wicker DC, Riggle PC. 20.  1986. 1,25-Dihydroxyvitamin D3 receptors identified in the rat heart. J. Mol. Cell Cardiol. 18:67–72 [Google Scholar]
  21. O'Connell TD, Simpson RU. 21.  1996. Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol. Int. 20:621–24 [Google Scholar]
  22. Fraga C, Blanco M, Vigo E. 22.  et al. 2002. Ontogenesis of the vitamin D receptor in rat heart. Histochem. Cell Biol. 117:547–50 [Google Scholar]
  23. Chen S, Glenn DJ, Ni W. 23.  et al. 2008. Expression of the vitamin D receptor is increased in the hypertrophic heart. Hypertension 52:1106–12 [Google Scholar]
  24. Wu J, Garami M, Cheng T, Gardner DG. 24.  1996. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J. Clin. Investig. 97:1577–88 [Google Scholar]
  25. O'Connell TD, Berry JE, Jarvis AK. 25.  et al. 1997. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am. J. Physiol. 272:H1751–H1758 [Google Scholar]
  26. Chen S, Law CS, Grigsby CL. 26.  et al. 2011. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 124:1838–47 [Google Scholar]
  27. Bodyak N, Ayus JC, Achinger S. 27.  et al. 2007. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. PNAS 104:16810–15 [Google Scholar]
  28. Walters MR, Ilenchuk TT, Claycomb WC. 28.  1987. 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+ uptake by cultured adult rat ventricular cardiac muscle cells. J. Biol. Chem. 262:2536–41 [Google Scholar]
  29. Weishaar RE, Simpson RU. 29.  1987. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am. J. Physiol. 253:E675–E683 [Google Scholar]
  30. Green JJ, Robinson DA, Wilson GE. 30.  et al. 2006. Calcitriol modulation of cardiac contractile performance via protein kinase C. J. Mol. Cell Cardiol. 41:350–59 [Google Scholar]
  31. Somjen D, Weisman Y, Kohen F. 31.  et al. 2005. 25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111:1666–71 [Google Scholar]
  32. Zehnder D, Bland R, Chana RS. 32.  et al. 2002. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J. Am. Soc. Nephrol. 13:621–29 [Google Scholar]
  33. Mitsuhashi T, Morris RC Jr, Ives HE. 33.  1991. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J. Clin. Investig. 87:1889–95 [Google Scholar]
  34. Wu-Wong JR, Nakane M, Ma J. 34.  et al. 2006. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 186:20–28 [Google Scholar]
  35. Cardus A, Parisi E, Gallego C. 35.  et al. 2006. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 69:1377–84 [Google Scholar]
  36. Mantell DJ, Owens PE, Bundred NJ. 36.  et al. 2000. 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ. Res. 87:214–20 [Google Scholar]
  37. Wakasugi M, Noguchi T, Inoue M. 37.  et al. 1991. Vitamin D3 stimulates the production of prostacyclin by vascular smooth muscle cells. Prostaglandins 42:127–36 [Google Scholar]
  38. Giulietti A, van Etten E, Overbergh L. 38.  et al. 2007. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res. Clin. Pract. 77:47–57 [Google Scholar]
  39. Rigby WF, Denome S, Fanger MW. 39.  1987. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J. Clin. Investig. 79:1659–64 [Google Scholar]
  40. Oh J, Weng S, Felton SK. 40.  et al. 2009. 1,25(OH)2 vitamin D inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 120:687–98 [Google Scholar]
  41. Kasuga H, Hosogane N, Matsuoka K. 41.  et al. 2002. Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. Biochem. Biophys. Res. Commun. 297:1332–38 [Google Scholar]
  42. Aihara K, Azuma H, Akaike M. 42.  et al. 2004. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J. Biol. Chem. 279:35798–802 [Google Scholar]
  43. Grimes DS, Hindle E, Dyer T. 43.  1996. Sunlight, cholesterol and coronary heart disease. QJM 89:579–89 [Google Scholar]
  44. Voors AW, Johnson WD. 44.  1979. Altitude and arteriosclerotic heart disease mortality in white residents of 99 of the 100 largest cities in the United States. J. Chronic Dis. 32:157–62 [Google Scholar]
  45. Rostand SG. 45.  1997. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 30:150–56 [Google Scholar]
  46. Fleck A. 46.  1989. Latitude and ischaemic heart disease. Lancet 1:613 [Google Scholar]
  47. Mortimer EA Jr, Monson RR, MacMahon B. 47.  1977. Reduction in mortality from coronary heart disease in men residing at high altitude. N. Engl. J. Med. 296:581–85 [Google Scholar]
  48. Enquselassie F, Dobson AJ, Alexander HM, Steele PL. 48.  1993. Seasons, temperature and coronary disease. Int. J. Epidemiol. 22:632–36 [Google Scholar]
  49. Douglas AS, Allan TM, Rawles JM. 49.  1991. Composition of seasonality of disease. Scott. Med. J. 36:76–82 [Google Scholar]
  50. Scragg R, Jackson R, Holdaway IM. 50.  et al. 1990. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int. J. Epidemiol. 19:559–63 [Google Scholar]
  51. Cigolini M, Iagulli MP, Miconi V. 51.  et al. 2006. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 29:722–24 [Google Scholar]
  52. Poole KE, Loveridge N, Barker PJ. 52.  et al. 2006. Reduced vitamin D in acute stroke. Stroke 37:243–45 [Google Scholar]
  53. Wang TJ, Pencina MJ, Booth SL. 53.  et al. 2008. Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503–11 [Google Scholar]
  54. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 54.  2008. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168:1174–80 [Google Scholar]
  55. Kilkkinen A, Knekt P, Aro A. 55.  et al. 2009. Vitamin D status and the risk of cardiovascular disease death. Am. J. Epidemiol. 170:1032–39 [Google Scholar]
  56. Anderson JL, May HT, Horne BD. 56.  et al. 2010. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am. J. Cardiol. 106:963–68 [Google Scholar]
  57. Wang L, Song Y, Manson JE. 57.  et al. 2012. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes 5:819–29 [Google Scholar]
  58. Lutsey PL, Michos ED, Misialek JR. 58.  et al. 2015. Race and Vitamin D binding protein gene polymorphisms modify the association of 25-hydroxyvitamin D and incident heart failure: the ARIC (Atherosclerosis Risk in Communities) study. J. Am. Coll. Cardiol. Heart Fail. 3:347–56 [Google Scholar]
  59. Pilz S, Marz W, Wellnitz B. 59.  et al. 2008. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J. Clin. Endocrinol. Metab. 93:3927–35 [Google Scholar]
  60. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. 60.  2014. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 348:g2035 [Google Scholar]
  61. Forman JP, Giovannucci E, Holmes MD. 61.  et al. 2007. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49:1063–69 [Google Scholar]
  62. 62.  Deleted in proof
  63. Burgaz A, Orsini N, Larsson SC, Wolk A. 63.  2011. Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis. J. Hypertens. 29:636–45 [Google Scholar]
  64. Kunutsor SK, Apekey TA, Steur M. 64.  2013. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur. J. Epidemiol. 28:205–21 [Google Scholar]
  65. Vimaleswaran KS, Cavadino A, Berry DJ. 65.  et al. 2014. Association of vitamin D status with arterial blood pressure and hypertension risk: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2:719–29 [Google Scholar]
  66. Hsia J, Heiss G, Ren H. 66.  et al. 2007. Calcium/vitamin D supplementation and cardiovascular events. Circulation 115:846–54 [Google Scholar]
  67. Trivedi DP, Doll R, Khaw KT. 67.  2003. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326:469 [Google Scholar]
  68. Prince RL, Austin N, Devine A. 68.  et al. 2008. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch. Intern. Med. 168:103–8 [Google Scholar]
  69. Brazier M, Grados F, Kamel S. 69.  et al. 2005. Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 27:1885–93 [Google Scholar]
  70. Michos ED, Blumenthal RS. 70.  2007. Vitamin D supplementation and cardiovascular disease risk. Circulation 115:827–28 [Google Scholar]
  71. Sugden JA, Davies JI, Witham MD. 71.  et al. 2008. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet. Med. 25:320–25 [Google Scholar]
  72. Joris PJ, Mensink RP. 72.  2015. Effects of supplementation with the fat-soluble vitamins E and D on fasting flow-mediated vasodilation in adults: a meta-analysis of randomized controlled trials. Nutrients 7:1728–43 [Google Scholar]
  73. Witham MD, Dove FJ, Dryburgh M. 73.  et al. 2010. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 53:2112–19 [Google Scholar]
  74. Witham MD, Price RJ, Struthers AD. 74.  et al. 2013. Cholecalciferol treatment to reduce blood pressure in older patients with isolated systolic hypertension: the VitDISH randomized controlled trial. JAMA Int. Med. 173:1672–79 [Google Scholar]
  75. Yiu YF, Yiu KH, Siu CW. 75.  et al. 2013. Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. Atherosclerosis 227:140–46 [Google Scholar]
  76. Manson JE, Bassuk SS, Lee IM. 76.  et al. 2012. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp. Clin. Trials 33:159–71 [Google Scholar]
  77. Beveridge LA, Struthers AD, Khan F. 77.  et al. 2015. Effect of Vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intl. Med. 175:745–54 [Google Scholar]
  78. Arora P, Song Y, Dusek J. 78.  et al. 2015. Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation 131:254–62 [Google Scholar]

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error